scheringplough
initi
format
independ
pregnanc
exposur
registri
respons
us
food
drug
administr
fda
postmarket
commit
monitor
evalu
safeti
ribavirin
pregnanc
second
ribavirin
product
hoffmanla
roch
ribavirin
approv
fda
similar
postmarket
commit
recommend
hoffmanla
roch
schere
plough
develop
joint
pregnanc
exposur
registri
ribavirin
enrol
within
usa
ribavirin
pregnanc
registri
establish
subsequ
year
five
addit
ribavirin
manufactur
join
registri
product
approv
use
usa
ribavirin
pregnanc
registri
cosponsor
manufactur
two
brand
product
merck
co
formerli
scheringplough
genentech
member
hoffmannla
roch
five
gener
product
aurobindo
pharma
sandoz
inc
teva
pharmaceut
usa
three
river
pharmaceut
zydu
pharmaceut
usa
accord
estim
hepat
c
viru
hcv
affect
approxim
world
popul
million
chronic
infect
global
estim
million
new
hcv
infect
occur
result
global
incid
rate
per
base
systemat
review
estim
number
us
resid
infect
hepat
c
least
million
rang
million
million
rang
million
current
infect
incid
usa
decreas
doubl
report
chronic
hcv
infect
lead
liver
diseas
approxim
infect
individu
develop
cirrhosi
period
year
die
hepatocellular
cancer
ribavirin
interferon
andor
directact
antivir
medic
use
treat
chronic
hepat
c
signific
teratogen
effect
demonstr
anim
speci
expos
ribavirin
therefor
ribavirin
contraind
women
pregnant
male
partner
women
pregnant
multipledos
halflif
ribavirin
day
ribavirin
may
persist
nonplasma
compart
month
therefor
recommend
pregnanc
avoid
treatment
also
month
follow
exposur
matern
exposur
describ
label
ribavirin
produc
signific
embryocid
andor
teratogen
effect
anim
speci
adequ
studi
conduct
femal
receiv
exposur
directli
malform
skull
palat
eye
jaw
limb
skeleton
gastrointestin
tract
report
malform
occur
dose
low
recommend
human
dose
ribavirin
teratogen
effect
observ
lowest
dose
ribavirin
studi
rat
rabbit
mgkgday
rat
rabbit
approxim
time
recommend
human
dose
ribavirin
incid
sever
teratogen
effect
increas
escal
drug
dose
howev
matern
toxic
effect
offspr
observ
peri
postnat
toxic
studi
rat
dose
oral
mgkgday
estim
human
equival
dose
mgkg
base
bodi
surfac
area
adjust
kg
adult
approxim
time
maximum
recommend
human
dose
ribavirin
studi
male
rodent
ribavirin
associ
revers
germ
cell
toxic
mutagen
decreas
epididym
sperm
count
ribavirin
also
induc
point
mutat
germ
cell
result
format
abnorm
sperm
howev
suspect
sperm
cell
mutat
may
result
cell
death
morpholog
abnorm
sperm
associ
infertil
maddrey
report
pregnanc
outcom
ten
women
took
ribavirin
pregnanc
four
result
miscarriag
four
termin
two
lost
followup
mishkin
describ
woman
directli
expos
ribavirin
month
prior
concept
result
normal
infant
labarga
et
al
report
woman
coinfect
hiv
hcv
receiv
treatment
pegyl
interferon
ribavirin
antiretrovir
therapi
first
week
pregnanc
deliv
healthi
infant
month
age
birth
defect
evid
hcv
hiv
infect
valentin
et
al
report
live
infant
trigonocephali
born
woman
exposur
valproat
thyroxin
throughout
entir
pregnanc
ribavirin
earli
pregnanc
discontinu
upon
diagnosi
pregnanc
rezvani
koren
report
normal
pregnanc
outcom
follow
system
inject
firsttrimest
matern
exposur
pregnant
woman
sever
acut
respiratori
syndrom
sar
sever
case
report
describ
outcom
pregnanc
indirect
ribavirin
exposur
exposur
occur
male
sexual
partner
clinic
trial
maddrey
report
outcom
pregnanc
follow
prenat
ribavirin
exposur
contact
male
sexual
partner
taken
ribavirin
pregnanc
result
two
healthi
live
born
infant
four
miscarriag
two
termin
seven
unknown
outcom
de
santi
et
al
report
seven
case
periconcept
male
exposur
result
six
normal
birth
outcom
one
spontan
abort
hegenbarth
et
al
report
two
case
male
partner
exposur
occur
month
prior
concept
result
live
born
infant
birth
defect
bianca
ettor
report
indirect
periconcept
exposur
advers
fetal
effect
signific
indirect
pregnanc
exposur
via
male
sexual
partner
unclear
hofer
et
al
measur
ribavirin
concentr
blood
semin
fluid
men
chronic
hcv
infect
treat
pegyl
combin
ribavirin
ribavirin
concentr
twofold
higher
semin
fluid
serum
level
semen
abnorm
common
prior
treatment
increas
treatment
pecou
et
al
evalu
man
expos
ribavirin
plu
pegyl
interferon
hcv
infect
subsequ
semen
paramet
sperm
dna
integr
treatment
experienc
decreas
percentag
progress
spermatozoa
number
motil
sperm
per
ejacul
addit
round
cellspermatozoa
ratio
suggest
spermatogen
abnorm
increas
treatment
return
baselin
level
month
treatment
sperm
dna
fragment
index
increas
treatment
treatment
end
month
treatment
remain
elev
month
treatment
author
conclud
alter
spermatogenesi
dna
packag
abnorm
persist
month
treatment
suggest
longer
pregnanc
avoid
period
discontinu
treatment
men
may
warrant
registri
primari
object
detect
signal
major
teratogen
effect
involv
ribavirin
exposur
pregnanc
within
period
prior
concept
exposur
ribavirin
incur
directli
indirectli
year
enrol
registri
reach
midpoint
intend
recruit
goal
paper
updat
review
background
data
experi
registri
began
augment
prior
review
data
collect
registri
incept
decemb
februari
analyz
sever
way
pregnant
woman
enrol
registri
woman
may
initi
enrol
process
healthcar
provid
may
initi
enrol
behalf
exposur
occur
male
sexual
contact
man
may
initi
enrol
therebi
allow
medic
record
confirm
ribavirin
dose
woman
may
selfenrol
healthcar
provid
may
enrol
behalf
manufactur
ribavirin
alert
pregnanc
exposur
primarili
report
consum
healthcar
provid
report
sent
registri
includ
registri
databas
minim
potenti
bias
ascertain
due
preferenti
report
abnorm
outcom
registri
encourag
enrol
earli
pregnanc
outcom
pregnanc
known
prenat
diagnosi
complet
pregnanc
due
high
preval
prenat
test
usa
feasibl
exclud
women
prenat
test
therefor
pregnant
women
may
enrol
registri
prospect
particip
prior
prenat
diagnos
includ
evid
birth
defect
women
abnorm
prenat
test
enrol
may
particip
registri
data
evalu
separ
retrospect
report
although
earli
report
prefer
enrol
may
occur
anytim
pregnanc
healthcar
provid
contribut
data
registri
typic
prescrib
ribavirin
eg
hepatologist
obstetrician
pediatrician
healthcar
provid
specialti
may
contact
woman
collect
inform
relat
ribavirin
pregnanc
health
infant
respect
particip
registri
requir
specif
offic
visit
intervent
minim
report
burden
facilit
report
registri
data
collect
form
brief
may
submit
registri
varieti
report
option
ie
telephon
fax
mail
email
clinic
data
particularli
data
relat
pregnanc
exposur
outcom
provid
woman
male
sexual
partner
must
confirm
healthcar
provid
enrol
followup
data
focus
ribavirin
exposur
famili
histori
birth
defect
matern
risk
factor
potenti
confound
pregnanc
outcom
includ
presenc
absenc
birth
defect
newborn
infant
health
indic
matern
followup
inform
obtain
pregnanc
around
time
pregnanc
outcom
infant
followup
data
collect
birth
month
year
age
outcom
pregnanc
classifi
one
follow
categori
live
birth
miscarriag
defin
pregnanc
loss
occur
week
gestat
induc
abort
stillbirth
defin
pregnanc
loss
occur
week
gestat
gestat
age
calcul
first
day
lmp
estim
date
deliveri
edd
lmp
avail
correct
edd
gener
ultrasound
avail
use
gestat
week
calcul
lmp
edd
first
trimest
begin
first
day
lmp
second
trimest
begin
week
third
trimest
begin
week
first
day
lmp
design
first
day
pregnanc
estim
exposur
gestat
age
registri
scientif
advisori
board
review
report
birth
defect
among
enrol
particip
board
member
list
registri
websit
registri
birth
defect
evalu
design
board
member
experienc
identif
classif
birth
defect
conduct
initi
expert
review
request
inform
necessari
provid
assess
relationship
exposur
outcom
birth
defect
evalu
assess
avail
inform
birth
defect
assign
organ
system
classif
macdp
classif
organ
system
classif
facilit
process
detect
potenti
signal
group
similar
defect
defect
similar
etiolog
togeth
macdp
code
improv
compar
registri
macdp
standard
name
convent
signal
detect
purpos
annual
board
review
new
report
birth
defect
base
evalu
assess
reach
consensu
final
determin
probabl
possibl
associ
time
ribavirin
exposur
develop
birth
defect
maintain
much
consist
madcp
birth
defect
surveil
system
possibl
without
miss
potenti
signal
registri
defin
birth
defect
major
structur
malform
chromosom
abnorm
diagnos
signssymptom
year
age
addit
definit
birth
defect
may
includ
casebycas
basi
subject
independ
review
cluster
two
condit
abnorm
structur
chromosom
defect
detect
prenat
evalu
pregnanc
gross
patholog
examin
abortu
deceas
infant
registri
exclud
birth
defect
attribut
prematur
eg
patent
ductu
arteriosu
patent
foramen
oval
inguin
hernia
case
definit
primari
analysi
popul
includ
prospect
enrol
women
within
usa
follow
attribut
direct
indirect
ribavirin
exposur
pregnanc
month
prior
pregnanc
healthcar
providerconfirm
exposur
outcom
inform
complet
followup
inform
pregnanc
outcom
end
pregnanc
due
greater
potenti
bia
subject
report
retrospect
outcom
pregnanc
known
clinic
studi
subject
exclud
primari
analysi
popul
analys
stratifi
direct
indirect
ribavirin
exposur
addit
period
earliest
exposur
ie
within
month
prior
concept
first
second
third
trimest
given
registri
voluntari
observ
populationbas
characterist
inclus
analysi
popul
requir
complet
healthcar
providerconfirm
data
limit
set
variabl
eg
ribavirin
exposur
pregnanc
outcom
birth
defect
statu
end
pregnanc
streamlin
data
collect
approach
reduc
report
burden
facilit
data
collect
therebi
increas
potenti
signal
detect
howev
due
miss
data
approach
often
limit
abil
assess
tempor
adequ
describ
report
birth
defect
birth
defect
rate
calcul
divid
number
live
born
stillborn
infant
greater
gestat
week
birth
defect
plu
number
induc
abort
birth
defect
number
live
birth
within
exposur
categori
use
avail
data
preliminari
birth
defect
rate
confid
interv
ci
calcul
analysi
conduct
version
sa
institut
cari
nc
usa
demograph
analysi
popul
present
tabl
mean
age
particip
women
time
enrol
year
littl
differ
women
direct
indirect
exposur
selfreport
race
ethnic
distribut
follow
white
hispan
black
asian
race
report
variabl
repres
age
clinic
condit
raceethn
consider
miss
valu
among
indirectli
expos
women
directli
expos
women
hepat
c
infect
report
nearli
directli
expos
women
three
indirectli
expos
women
time
analysi
one
woman
reportedli
receiv
tripl
therapi
pregnanc
includ
directact
antivir
medic
telaprevir
tabl
prenat
test
prior
enrol
report
women
analysi
popul
tabl
ten
women
prenat
test
time
unknown
pre
postenrol
howev
birth
defect
report
tabl
among
women
primari
analysi
popul
ribavirin
exposur
categor
period
earliest
exposur
occur
month
prior
concept
first
trimest
tabl
two
women
expos
second
trimest
indirect
exposur
third
trimest
exposur
report
among
pregnanc
enrol
individu
pregnanc
outcom
ie
fetus
infant
includ
one
set
liveborn
twin
expos
ribavirin
directli
tabl
among
pregnanc
outcom
liveborn
infant
miscarriag
induc
abort
stillbirth
slightli
liveborn
infant
among
indirectli
expos
outcom
directli
expos
outcom
tabl
proport
miscarriag
among
directli
expos
pregnanc
outcom
compar
among
indirectli
expos
outcom
although
base
small
number
miscarriag
consider
frequent
among
firsttrimest
exposur
women
expos
prior
concept
tabl
among
women
induc
abort
indic
exposur
ribavirin
potenti
birth
defect
influenti
factor
cite
reason
unrel
ribavirin
provid
reason
therefor
among
women
provid
reason
induc
abort
indic
exposur
ribavirin
contribut
factor
report
birth
defect
among
induc
abort
howev
inform
unknown
miss
liveborn
infant
primari
analysi
popul
followup
data
assess
followup
data
either
infant
without
pediatr
followup
data
presenc
absenc
birth
defect
determin
use
data
collect
time
birth
often
report
obstetrician
primari
reason
lack
followup
data
inabl
identifi
engag
infant
healthcar
provid
registri
receiv
report
outcom
birth
defect
primari
analysi
popul
among
liveborn
infant
tabl
directli
expos
infant
seven
one
report
birth
defect
ci
indirectli
expos
infant
four
one
report
birth
defect
ci
infant
birth
defect
nine
structur
defect
two
infant
chromosomalgenet
diseas
unlik
relat
ribavirin
exposur
pattern
suggest
common
etiolog
seen
tabl
among
women
enrol
registri
lost
followup
tabl
medic
confirm
enrol
criteria
women
selfenrol
lowest
rate
loss
followup
follow
women
initi
report
healthcar
provid
women
report
registri
manufactur
pharmacovigil
network
highest
rate
lost
followup
rate
base
combin
group
n
women
analysi
popul
n
plu
lost
followup
medic
confirm
enrol
criteria
n
ribavirin
pregnanc
registri
design
evalu
potenti
human
teratogen
prenat
exposur
ribavirin
year
registri
reach
midpoint
enrol
eleven
outcom
birth
defect
report
among
liveborn
infant
tabl
nine
infant
structur
defect
two
infant
torticolli
two
infant
hypospadia
two
infant
hearingrel
condit
deaf
hear
loss
one
infant
polydactyli
postaxi
right
foot
neonat
tooth
one
infant
ventricular
septal
defect
cyst
fourth
ventricl
brain
one
infant
atrial
septal
defect
asd
two
infant
genet
condit
one
dehydrogenas
defici
one
syndrom
conserv
avoid
miss
potenti
signal
registri
count
infant
birth
defect
case
calcul
direct
indirect
birth
defect
rate
tabl
howev
sever
infant
altern
origin
may
etiolog
two
infant
birth
defect
chromosomalgenet
disord
tabl
case
number
therefor
unlik
condit
relat
ribavirin
among
structur
defect
two
infant
famili
histori
defect
suggest
inherit
caus
predisposit
one
infant
hypospadia
patern
histori
hypospadia
tabl
case
number
infant
polydactyli
postaxi
right
foot
neonat
tooth
famili
histori
defect
tabl
case
number
two
infant
torticolli
tabl
case
number
one
report
intermitt
therefor
may
attribut
posit
utero
tabl
case
number
infant
hear
loss
tabl
case
number
mention
condit
routin
followup
abnorm
first
report
registri
infant
month
age
particip
registri
complet
hear
loss
report
mother
confirm
healthcar
provid
hear
loss
delay
onset
characterist
congenit
deaf
suggest
prenat
factor
eg
genet
diseas
congenit
cytomegaloviru
infect
postnat
environment
factor
although
none
report
final
regard
infant
secundum
asd
tabl
case
number
report
base
auscult
murmur
birth
registri
unabl
obtain
inform
sever
howev
registri
learn
month
age
infant
transthorac
echocardiogram
indic
secundum
asd
resolv
addit
cardiac
abnorm
found
infant
includ
birth
defect
rate
case
defect
present
birth
consist
handl
case
compar
popul
macdp
registri
report
varieti
condit
among
birth
defect
case
detect
pattern
among
subject
similar
anim
data
suggest
teratogen
mechan
strength
evid
surround
associ
ribavirin
human
birth
defect
weak
birth
defect
rate
interpret
cautious
sever
birth
defect
current
includ
direct
exposur
birth
defect
rate
ci
indirect
exposur
rate
ci
may
unrel
exposur
macdp
birth
defect
rate
within
ci
indirect
exposur
direct
exposur
howev
larg
varianc
estim
indic
calcul
rel
risk
prematur
unreli
given
current
enrol
far
short
desir
number
base
sampl
size
calcul
abil
estim
risk
reach
conclus
direct
indirect
exposur
limit
regard
embryocid
activ
report
anim
studi
registri
report
one
stillbirth
overal
miscarriag
rate
consist
estim
miscarriag
us
gener
popul
examin
miscarriag
rate
trimest
earliest
exposur
indic
consider
higher
rate
miscarriag
among
women
follow
first
trimest
exposur
direct
indirect
exposur
group
signific
find
difficult
assess
given
small
number
women
strata
limit
studi
design
captur
earli
miscarriag
ribavirin
use
combin
treatment
chronic
hepat
c
infect
relev
note
shown
preclin
anim
studi
abortifaci
properti
pace
enrol
registri
slower
expect
like
result
two
factor
reduc
potenti
pregnanc
exposur
introduct
new
directact
ribavirinfre
antivir
medic
regimen
hepat
c
riskminim
activ
emphas
pregnanc
avoid
associ
ribavirin
riskminim
activ
ribavirin
includ
fda
pregnanc
categori
x
design
box
warn
prescrib
inform
regard
pregnanc
avoid
warn
medic
guid
need
avoid
pregnanc
emphas
promin
place
document
activ
effect
avail
expos
pregnanc
expect
decreas
consum
becom
awar
import
pregnanc
avoid
take
ribavirin
month
ribavirin
stop
approxim
registri
particip
chose
induc
abort
ribavirinexpos
pregnanc
rate
consist
overal
gener
popul
estim
usa
registri
rate
gener
popul
rate
describ
two
distinctli
differ
popul
registri
induc
abort
rate
may
underestim
among
ribavirinexpos
pregnant
women
repres
popul
women
decid
enrol
registri
termin
pregnanc
thereaft
registri
unabl
quantifi
number
women
choos
termin
pregnanc
prior
interact
registri
concern
enrol
women
choos
induc
abort
due
fear
birth
defect
relat
ribavirin
exposur
underscor
import
complet
enrol
registri
inform
decis
made
safeti
ribavirin
exposur
pregnanc
onehalf
pregnant
women
compris
analysi
popul
indirectli
expos
mani
question
remain
safeti
indirect
pregnanc
exposur
ribavirin
particularli
whether
ribavirin
contain
semin
fluid
exert
deleteri
effect
sperm
fertil
ova
scientif
evid
support
ribavirin
genotox
sperm
cell
mice
rat
human
genotox
data
base
peripher
blood
smear
human
sperm
cell
studi
human
subject
shown
concentr
ribavirin
semin
fluid
may
higher
initi
expect
given
observ
design
voluntari
natur
registri
miss
data
time
lack
critic
detail
necessari
optim
character
birth
defect
associ
ribavirin
limit
studi
miss
data
famili
histori
birth
defect
problemat
birth
defect
may
appear
tempor
relat
ribavirin
exposur
like
reason
birth
defect
genet
birth
defect
may
go
unreport
due
incomplet
infant
followup
data
exampl
neurosensori
cardiac
defect
may
observ
year
age
also
registri
unabl
engag
pediatrician
birth
defect
typic
identifi
later
infanc
would
captur
followup
may
underreport
overestim
birth
defect
rate
may
occur
due
conserv
approach
use
registri
whose
assessor
blind
exposur
classifi
birth
defect
avoid
miss
potenti
signal
registri
classifi
infant
birth
defect
case
calcul
direct
indirect
birth
defect
rate
may
clear
associ
genet
environment
factor
addit
registri
high
lost
followup
rate
vari
type
initi
report
ie
patient
healthcar
provid
registri
sponsor
limit
precis
estim
rate
power
comparison
macdp
avail
appropri
diseasespecif
comparison
group
popul
pregnant
women
hcv
infect
expos
ribavirin
pregnanc
pose
consider
challeng
estim
rel
risk
ongo
basi
ribavirin
pregnanc
registri
research
medic
pediatr
literatur
obtain
appropri
background
rate
becom
avail
date
registri
success
identifi
pregnanc
outcom
data
comparison
group
women
hcv
taken
ribavirin
registri
exposur
window
method
use
ribavirin
pregnanc
registri
differ
consider
cdc
macdp
limit
valid
studi
design
macdp
populationbas
activ
surveil
system
base
birth
defect
ascertain
retrospect
record
review
metropolitan
atlanta
georgia
area
contrast
registri
voluntari
prospect
studi
enrol
report
pregnanc
activ
solicit
pregnanc
outcom
anywher
usa
macdp
collect
data
liveborn
infant
fetus
week
age
older
includ
pregnanc
outcom
data
induc
abort
wherea
registri
collect
data
birth
outcom
gestat
age
given
limit
comparison
macdp
must
interpret
caution
connel
et
al
conduct
retrospect
cohort
studi
florida
birth
use
birth
certif
record
link
hospit
discharg
data
found
women
hepat
c
infect
like
infant
congenit
anomali
odd
ratio
ci
variabl
repres
congenit
anomali
composit
congenit
anomali
report
secondari
databas
use
studi
matern
medic
use
evalu
cohort
date
prior
introduct
directact
antivir
agent
hcv
usa
therefor
appear
prenat
ribavirin
exposur
pregnanc
rule
popul
thu
cohort
may
unexpos
popul
connel
et
al
report
women
hepat
c
infant
congenit
anomali
rate
higher
macdp
rate
fall
ribavirin
pregnanc
registri
rate
direct
exposur
indirect
exposur
base
pattern
birth
defect
report
preliminari
find
suggest
clear
signal
human
teratogen
ribavirin
howev
current
sampl
size
insuffici
reach
definit
conclus
studi
initi
ribavirin
rel
new
medic
limit
data
use
particularli
among
pregnant
women
sinc
time
avail
secondari
data
research
eg
claim
data
electron
health
record
data
experi
ribavirin
increas
studi
topic
use
larg
secondari
databas
includ
medic
exposur
may
provid
data
voluntari
registri
howev
feasibl
option
nonetheless
secondari
data
ribavirin
use
could
provid
estim
extent
ribavirin
use
target
popul
therebi
improv
enrol
project
complet
registri
enrol
dissemin
find
inform
practic
continu
delay
registri
meet
sampl
size
goal
despit
diminish
popul
enrol
expos
pregnanc
pregnanc
exposur
continu
occur
registri
continu
enrol
direct
indirect
pregnanc
exposur
ribavirin
optim
awar
activ
healthcar
provid
encourag
report
expos
pregnanc
registri
addit
inform
avail
wwwribavirinpregnancyregistrycom
